Public Release: 

Bio-molecules in human breast milk stop inflammation

BWH researchers investigate the protective health properties of breast milk

Brigham and Women's Hospital

Human breast milk, which provides essential nutrients and antibodies to newborns, has long been known to play an important role in infant development and the immune system. In a new study published in Mucosal Immunology, researchers from Brigham and Women's Hospital (BWH) report that human breast milk serves as a reservoir for bio-molecules that help to resolve inflammation and combat infection.

"Finding a reservoir of these inflammation-resolving molecules at bioactive levels was a big surprise for us," said co-corresponding author Charles Serhan, PhD, DSc, director of BWH's Center for Experimental Therapeutics and Reperfusion Injury. "We've identified some of these molecular signals in other organs and tissue in the human body, but this is the first time we've seen them all in one place."

Using a comprehensive profiling technique, the team was able to uncover a milieu of molecules known as specialized pro-resolving mediators (SPMs) in human breast milk and found that each of these molecules helped resolve inflammation and stimulate immune response in preclinical models.

Certain SPMs have been detected in breast milk before, but this is the first time that such a wide variety of bioactive molecules have been uncovered, including molecules that help clear infections, reduce inflammation, combat pain and heal wounds.

"Human breast milk has many important, protective properties," said co-corresponding author Hildur Arnardottir, PhD, who conducted this work while a post-doctoral fellow in the Serhan lab. "This study extends our understanding of the benefits breast milk provides."

The Serhan lab, which focuses on identifying and elucidating the structures of bioactive molecules, has made critical discoveries over the last two decades that have illuminated the biochemical signaling pathways that resolve and control inflammation and pain associated with disease and injury recovery. In its most recent study, the lab used rigorous detection techniques to look for such signals in human breast milk. The team uncovered a profiling signature consisting of 20 molecules with pro-resolving properties. They then tested the contributions of samples from breast milk as well as individual molecules in both animal and cellular models of infection, measuring the length of time until resolution.

The team also tested human milk samples from subjects with mastitis, an infection of the breast tissue that causes pain and inflammation. They found that SPM levels were much lower in milk from mastitis and did not resolve inflammation and infection to the degree that breast milk from non-mastitis samples did. The team also tested cow's milk and infant formula and did not detect SPM levels.

Further studies are needed to understand the role of SPMs in infants who have been given human breast milk and the precise way SPMs may help an infant's immune system mature, but the research team hopes that their study will open up new areas of investigation for the field.

"Our results suggest a role for SPM in modulating inflammation, infection and stimulating resolution during early immune development, and further reinforce the importance of human breast milk for infants," said Serhan.


Other researchers who contributed to this work include Sarah K . Orr and Jesmond Dalli. Funding for this research was provided by NIH grant P01GM095467, Solutex, an Arthritis Foundation Postdoctoral Fellowship Award and a Canadian Institutes of Health Research Fellowship Award. Serhan is an inventor on patents (resolvins) assigned to BWH and licensed to Resolvyx Pharmaceuticals. Serhan is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company.

Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 4.2 million annual patient visits, nearly 46,000 inpatient stays and employs nearly 16,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Brigham Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $600 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative as well as the TIMI Study Group, one of the premier cardiovascular clinical trials groups. For more information, resources and to follow us on social media, please visit BWH's online newsroom.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.